

Ref: NLL/CS/2025- 575

September 16, 2025

To,

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001

Scrip Code: 532649

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“LODR Regulations”).

Sub.: Sale, transfer and delivery of the assets of the Company in relation to its menthol business (“Assets Sale”) to Ceph Lifesciences Private Limited (“Purchaser”)

Dear Sir/ Madam,

This is in continuation of disclosures regarding the Assets Sale provided vide letter no. NLL/CS/2025-514 dated July 07, 2025 and Annexure 2 thereof.

In this regard, please be informed that Nectar Lifesciences Limited and the Purchaser have mutually agreed to extend the expected completion date of the Asset Sale to on or before October 20, 2025.

The other relevant disclosures, regarding the Assets Sale, has already been provided as per Annexure no. 2 vide letter no. NLL/CS/2025-514 dated July 07, 2025.

This is for your information and records please.

Thanking you,

Yours faithfully

For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)

Company Secretary & Compliance Officer